
Frequent urination at night can help protect against bladder cancer, says a new study.
A team of Spanish and American scientists suggests direct association between the number of times people get up at night to urinate and protection against bladder cancer.
Advertisement
Juan Alguacil, a researcher from the University of Huelva and one of the authors, suggest that night-time is usually the period during which there is the longest time interval between urination.
"The length of time carcinogenic agents, such as those from tobacco for example, are present in the urine, constitutes an important factor towards the likelihood of developing bladder cancer," Science Daily quoted Alguacil as saying.
During the study, the researchers analysed the urinary frequency in 884 recently diagnosed bladder cancer cases and in 996 non-cancer 'control patients'
They found that those people who usually get up at night at least twice to pass urine reduced their risk of suffering from bladder cancer by 40-59 pct.
This "protective effect" was found in both men and women and did not relate to the consumption of tobacco or the quantity of water they drank.
The research is published in International Journal of Cancer.
Source: ANI
SRM/SK
Advertisement
During the study, the researchers analysed the urinary frequency in 884 recently diagnosed bladder cancer cases and in 996 non-cancer 'control patients'
They found that those people who usually get up at night at least twice to pass urine reduced their risk of suffering from bladder cancer by 40-59 pct.
This "protective effect" was found in both men and women and did not relate to the consumption of tobacco or the quantity of water they drank.
The research is published in International Journal of Cancer.
Source: ANI
SRM/SK
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News

The mechanism by which the kinases cause inflammation has been discovered by scientists.

Pancreatic cancer cases are on the rise. The biomarker approach could reduce the chance of developing pancreatic cancer.

New combination of medications trametinib and entinostat were found to decrease lung cancer in mice.

Combination treatment with TALZENNA and XTANDI was found to benefit prostate cancer patients, revealed study.

In leukemia patients, reduced amounts of dietary vitamin A is associated with a higher risk and severity of pancreatitis.